Pap tests and HPV infection: Advances in screening and interpretation

Postgraduate Medicine

Volumn 118, Issue 2, 2005, Pages 37-46

  Buechler, Elizabeth J ^a  

^a HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; CANCER INCIDENCE; CANCER RISK; CELL DAMAGE; CLINICAL PRACTICE; CONFERENCE PAPER; HUMAN; NONHUMAN; PAPANICOLAOU TEST; RISK FACTOR; SQUAMOUS CELL; UTERINE CERVIX CARCINOMA; VIRUS DETECTION; VIRUS INFECTION; WART VIRUS; DIFFERENTIAL DIAGNOSIS; EVIDENCE BASED MEDICINE; FEMALE; MASS SCREENING; PAPILLOMA VIRUS; PATHOLOGY; PRACTICE GUIDELINE; PRIMARY PREVENTION; REVIEW; STANDARD; STATISTICS; UNITED STATES; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIROLOGY; WOMEN'S HEALTH;

CERVICAL INTRAEPITHELIAL NEOPLASIA; DIAGNOSIS, DIFFERENTIAL; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRACTICE GUIDELINES; PRIMARY PREVENTION; RISK FACTORS; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; WOMEN'S HEALTH;

EID: 25144525135     PISSN: 00325481     EISSN: 12182583     Source Type: Journal    
DOI: 10.3810/pgm.2005.08.1693     Document Type: Conference Paper

References (25)

1. Munoz N, Bosch FX, de Sanjose S, et al; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348(6):518-27
2. Palefsky JM. Anal squamous intraepithelial lesions: relation to HIV and human papillomavirus infection. J Acquir Immune Defic Syndr 1999;21(Suppl 1):S42-8
3. Lacey HB, Wilson GE, Tilston P, et al. A study of anal intraepithelial neoplasia in HIV positive homosexual men. Sex Transm Infect 1999;75(3):172-7
4. Monk BJ, Burger RA, Lin F, et al. Prognostic significance of human papillomavirus DNA in vulvar carcinoma. Obstet Gynecol 1995;85(5 Pt 1):709-15
5. Iversen T, Tretli S. Intraepithelial and invasive squamous cell neoplasia of the vulva: trends in incidence, recurrence, and survival rate in Norway. Obstet Gynecol 1998;91(6):969-72
6. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338(7):423-8
7. Smith EM, Johnson SR, Ritchie JM, et al. Persistent HPV infection in postmenopausal age women. Int J Gynaecol Obstet 2004;87(2):131-7
8. Wright TC, Cox JT. Clinical uses of human papillomavirus (HPV) DNA testing. Hagerstown, Md: American Society for Colposcopy and Cervical Pathology, 2004
9. Schlecht NF, Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001;286(24):3106-14
10. American College of Obstetricians and Gynecologists. ACOG practice bulletin. Cervical cytology screening. Number 45, August 2003. Obstet Gynaecol 2003;102(2):417-27
11. Saslow D, Runowicz CD, Solomon D, et al; American Cancer Society. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002;52(6):342-62
12. Saint M, Gildengorin G, Sawaya GF. Current cervical neoplasia screening practices of obstetrician/gynecologists in the US. Am J Obstet Gynecol 2005;192(2):414-21
13. Abulafia O, Pezzullo JC, Sherer DM. Performance of ThinPrep liquid-based cervical cytology in comparison with conventionally prepared Papanicolaou smears: a quantitative survey. Gynecol Oncol 2003;90(1):137-44
14. Braly P, Sedlacek T, Kinney W, et al. Reporting the potential benefits of new technologies for cervical cancer screening. J Low Genit Tract Dis 2001;5(2):73-81
15. Diaz-Rosario LA, Kabawat SE. Performance of a fluidbased, thin-layer Papanicolaou smear method in the clinical setting of an independent laboratory and an outpatient screening population in New England. Arch Pathol Lab Med 1999;123(9):817-21
16. Obwegeser JH, Brack S. Does liquid-based technology really improve detection of cervical neoplasia? A prospective, randomized trial comparing the ThinPrep Pap test with the conventional Pap test, including follow-up of HSIL cases. Acta Cytol 2001;45(5):709-14
17. Wright TC Jr, Cox JT, Massad LS, et al; ASCCP-Sponsored Consensus Conference. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 2002;287(16):2120-9
18. Davey DD, Austin RM, Birdsong G, et al; American Society for Colposcopy and Cervical Pathology. ASCCP patient management guidelines: Pap test specimen adequacy and quality indicators. J Low Genit Tract Dis 2002;6(3):195-9
19. Mintzer M, Curtis P, Resnick JC, et al. The effect of the quality of Papanicolaou smears on the detection of cytologic abnormalities. Cancer 1999;87(3):113-7
20. Mitchell HS. Longitudinal analysis of histologic high-grade disease after negative cervical cytology according to endocervical status. Cancer 2001;93(4):237-40
21. Selvaggi SM. Reporting of atypical squamous cells, cannot exclude a high-grade squamous intraepithelial lesion (ASC-H) on cervical samples: Is it significant? Diagn Cytopathol 2003;29(1):38-41
22. Solomon D, Schiffman M, Tarone R; ALTS Study Group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001;93(4):293-9
23. Levine L, Lucci JA III, Dinh TV. Atypical glandular cells: new Bethesda terminology and management guidelines. Obstet Gynecol Surv 2003;58(6):399-406
24. Sharpless KE, Schnatz PF, Mandavilli S, et al. Lack of adherence to practice guidelines for women with atypical glandular cells on cervical cytology. Obstet Gynecol 2005;105(3):501-6
25. Harper DM, Franco EL, Wheeler C, et al; GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364(9447):1757-65